Neuraxis announces new medical policy with two health insurers

NeurAxis (NRXS) announced medical policy coverage for Percutaneous Electrical Nerve Field Stimulation, PENFS, covering two health insurers, with approximately 700,000 total members in Connecticut and Massachusetts. This medical policy will bring our national total coverage for PENFS to roughly 53 million, with more decisions from major payers still pending. NeurAxis’ PENFS technology, IB-Stim, is FDA-cleared for functional abdominal pain associated with irritable bowel syndrome and Pediatric Functional Dyspepsia in adolescents 8-21 years old. IB-Stim is a non-surgical device that sends gentle electrical impulses into cranial nerve bundles in the ear. There are currently no FDA-approved drug therapies for children with abdominal pain-related disorders of the gut-brain interaction. Off-label, prescription drugs are often used to treat children despite poor evidence of efficacy and the potential for serious side effects.